Quest Magazine

Former National Goodwill Ambassador to be Featured on MDA Show of Strength Telethon

Star Lineup Set for MDA Show of Strength Telethon this Labor Day Weekend

MDA President and CEO Takes the #ALSIceBucketChallenge

CHIGAGO, August 15, 2014 – Having a bucket of ice water dumped on your head may not seem dignified, but it is certainly helping MDA and other ALS-fighting organizations raise awareness and funds as the viral social media craze continues to sweep across America.  

Today, Steven M. Derks, President and CEO of the Muscular Dystrophy Association, joined the ranks of tens of thousands of people willing to get chilled in the ALS Ice Bucket Challenge.

DMD: Sarepta Updates Community on Eteplirsen, Other Compounds

Cambridge, Mass.-based biotechnology company Sarepta Therapeutics updated the Duchenne muscular dystrophy (DMD) community about its pipeline of drugs in development for this disorder via an Aug.

MG: Multicenter Trial of Rituximab Opens

A phase 2 clinical trial of the drug rituximab (Rituxan) in adults with myasthenia gravis (MG) is now open at 15 U.S. centers with plans for additional sites.

Rituximab suppresses a specific part of the body's immune system and is approved by the U.S. Food and Drug Administration (FDA) to treat rheumatoid arthritis and other disorders.

First Drug for Duchenne Muscular Dystrophy Gets 'Conditional Approval' in Europe

DMD: Ataluren Receives Conditional Approval in Europe

Update (Oct. 24, 2014): Enrollment for the phase 3 trial of ataluren is complete, with results expected in the second half of 2015. See the PTC press release of Sept. 9, 2014.


original story:

PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ for the treatment of Nonsense Mutation Duchenne Muscular Dystrophy

ISIS-SMNRx to Be Tested in Phase 3 Trial in Infants With SMA

California-based Isis Pharmaceuticals has announced the opening of a phase 3 clinical trial of its experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA), a muscle-weakening disease that results from loss of nerve cells in the spinal cord.

Safeway Inc. and The Safeway Foundation Fundraising Campaign to Support Programs for People with Disabilities